Download PDF
Geburtshilfe Frauenheilkd 2016; 76(02): 164-169
DOI: 10.1055/s-0035-1558185
Review
GebFra Science
Georg Thieme Verlag KG Stuttgart · New York

PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives

PARP-Inhibitoren beim rezidivierenden Ovarialkarzinom, aktuelle Therapieoptionen und zukünftige Entwicklungen
J. Sehouli
1   Universitätsklinikum Berlin Charité, Klinik für Gynäkologie, Charté Comprehensive Cancer Center (CCCC), Berlin
,
E. I. Braicu
2   Universitätsklinikum Berlin Charité, Campus Virchow-Klinikum, Klinik für Gynäkologie, Charté Comprehensive Cancer Center (CCCC), Berlin
,
R. Chekerov
2   Universitätsklinikum Berlin Charité, Campus Virchow-Klinikum, Klinik für Gynäkologie, Charté Comprehensive Cancer Center (CCCC), Berlin
› Author Affiliations
Further Information

Publication History

received 15 June 2015
revised 16 August 2015

accepted 14 September 2015

Publication Date:
29 February 2016 (online)

Also available at
   Permissions and Reprints

Abstract

More than simply a promising management option, PARP inhibitors can be regarded as a milestone in the development of personalised treatment of recurrent ovarian carcinoma. Their mechanism of action, known as “synthetic lethality”, is dependent on functional differences of the DNA repair mechanisms of healthy cells and tumour cells; cells that repair DNA damage less efficiently are particularly sensitive to PARP inhibitors. Olaparib, licensed for use this year, is the best-studied PARP inhibitor used for treatment of high-grade serous ovarian carcinoma (HGSC). The efficacy of PARP inhibitors appears to be increased when used in combination with other treatments.

Zusammenfassung

PARP-Inhibitoren stellen nicht nur eine sehr vielversprechende Behandlungsmöglichkeit dar, ihre Entwicklung kann zudem als Meilenstein bei der Einführung einer personalisierten Medizin in der Behandlung des rezidivierten Ovarialkarzinoms betrachtet werden. Ihre Wirkungsweise, auch als synthetische Letalität bezeichnet, beruht auf den unterschiedlichen Funktionalitäten der DNA-Reparaturmechanismen bei gesunden und Tumorzellen. Zellen, die eine verminderte Fähigkeit aufweisen, DNA-Schäden effizient zu reparieren, sind besonders sensitiv gegenüber PARP-Inhibitoren. Bei Olaparib handelt es sich um den beim High-grade, serösen Ovarialkarzinom (HGSC) inzwischen am besten untersuchten und seit diesem Jahr zugelassenen PARP-Inhibitor. Die Kombination von PARP-Inhibitoren mit anderen Therapieansätzen scheint die Effektivität der PARP-Inhibitoren zu steigern.

Key words

ovarian cancer - BRCA - molecular pathway - PARP inhibitors

Schlüsselwörter

Ovarialkarzinom - BRCA - Signaltransduktionsweg - PARP-Inhibitor

Supporting Information

 

  • References

  • 1 Robert Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V., Hrsg. Krebs in Deutschland 2009/2010. 9. Ausgabe. Berlin: 2013
    Google Scholar
  • 2 Marchetti C, Imperiale L, Gasparri ML et al. Olaparib, PARP1 inhibitor in ovarian cancer. Expert Opin Investig Drugs 2012; 21: 1575-1584
    CrossrefPubMedGoogle Scholar
  • 3 Antoniou A, Pharoah PD, Narod S et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117-1130
    CrossrefPubMedGoogle Scholar
  • 4 Bolton KL, Chenevix-Trench G, Goh C et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 2012; 307: 382-390
    CrossrefPubMedGoogle Scholar
  • 5 The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-615
    CrossrefPubMedGoogle Scholar
  • 6 Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014; 15: 852-861
    CrossrefPubMedGoogle Scholar
  • 7 Rouleau M, Patel A, Hendzel MJ et al. PARP inhibition: PARP1 and beyond. Nat Rev Cancer 2010; 10: 293-301
    CrossrefPubMedGoogle Scholar
  • 8 Do K, Cehn AP. Molecular pathways: targeting PARP in cancer treatment. Clin Cancer Res 2012; 19: 977-984
    PubMedGoogle Scholar
  • 9 Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature 2012; 481: 287-294
    CrossrefPubMedGoogle Scholar
  • 10 Patel AG, Sarkaria JN, Kaufmann SH. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci U S A 2011; 108: 3406-3411
    CrossrefPubMedGoogle Scholar
  • 11 Murai J, Huang SY, Das BB et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res 2012; 72: 5588-5599
    CrossrefPubMedGoogle Scholar
  • 12 Mateo J, Ong M, Tan DS et al. Appraising iniparib, the PARP inhibitor that never was–what must we learn?. Nat Rev Clin Oncol 2013; 10: 688-696
    CrossrefPubMedGoogle Scholar
  • 13 Fong PC, Yap TA, Boss DS et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010; 28: 2512-2519
    CrossrefPubMedGoogle Scholar
  • 14 Audeh MW, Carmichael J, Penson RT et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 376: 245-251
    CrossrefPubMedGoogle Scholar
  • 15 Gelmon KA, Tischkowitz M, Mackay H et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011; 12: 852-861
    CrossrefPubMedGoogle Scholar
  • 16 Kaye SB, Lubinski J, Matulonis U et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 2012; 30: 372-379
    CrossrefPubMedGoogle Scholar
  • 17 Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012; 366: 1382-1392
    CrossrefPubMedGoogle Scholar
  • 18 Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-134
    CrossrefPubMedGoogle Scholar
  • 19 Kummar S, Kinders R, Gutierrez ME et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol 2009; 27: 2705-2711
    CrossrefPubMedGoogle Scholar
  • 20 Kummar S, Ji J, Morgan R et al. A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin Cancer Res 2012; 18: 1726-1734
    CrossrefPubMedGoogle Scholar
  • 21 EMCC. Veliparib plus temozolomide in metastatic melanoma trends toward increased PFS but results are not statistically significant. Oncology (Williston Park) 2011; 25: 1213 1232
    PubMedGoogle Scholar
  • 22 Kummar S, Chen A, Ji J et al. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res 2011; 71: 5626-5634
    CrossrefPubMedGoogle Scholar
  • 23 Coleman RL, Sill M, Aghajanian C et al. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation. SGO Annual Meeting. Abstr. 136; presented March 25, 2014.
    PubMedGoogle Scholar
  • 24 Jones P, Altamura S, Boueres J et al. Discovery of 2-{4-[(3 S)-piperidin-3-yl]phenyl}-2 H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem 2009; 52: 7170-7185
    CrossrefPubMedGoogle Scholar
  • 25 Sandhu SK, Schelman WR, Wilding G et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol 2014; 14: 882-892
    PubMedGoogle Scholar
  • 26 Ihnen M, zu Eulenburg C, Kolarova T et al. Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer. Mol Cancer Ther 2013; 12: 1002-1015
    CrossrefPubMedGoogle Scholar
  • 27 Kristeleit RS, Shapiro G, LoRusso P et al. A phase I dose escalation and PK study of continuous oral rucaparib in patients with advanced solid tumors. J Clin Oncol 2013; 31 (Suppl.) Abstr. 2585
    PubMedGoogle Scholar
  • 28 Kristeleit RS, Burris HA, LoRusso P et al. Phase 1/2 study of oral rucaparib: final phase 1 results. J Clin Oncol 2014; 32 (Suppl.) Abstr. 2573
    PubMedGoogle Scholar
  • 29 Shen Y, Rehman FL, Feng Y et al. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res 2013; 19: 5003-5015
    CrossrefPubMedGoogle Scholar
  • 30 DeBono JS, Mina LA, Gonzalez M et al. First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors. J Clin Oncol 2013; 31 (Suppl.) Abstr. 2580
    CrossrefPubMedGoogle Scholar
  • 31 Reinbolt RE, Hays JL. The role of PARP inhibitors in the treatment of gynecologic malignancies. Front Oncol 2013; 3: 237
    PubMedGoogle Scholar
  • 32 Oza AM, Cibula D, Oaknin A et al. Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label phase II study. J Clin Oncol 2012; 30 (Suppl.) Abstr. 5001
    PubMedGoogle Scholar
  • 33 Juvekar A, Burga LN, Hu H et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov 2012; 2: 1048-1063
    CrossrefPubMedGoogle Scholar
  • 34 Bindra RS, Schaffer PJ, Meng A et al. Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol Cell Biol 2004; 24: 8504-8518
    CrossrefPubMedGoogle Scholar
  • 35 Bindra RS, Gibson SL, Meng A et al. Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. Cancer Res 2005; 65: 11597-11604
    CrossrefPubMedGoogle Scholar
  • 36 Chan N, Pires IM, Bencokova Z et al. Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Cancer Res 2010; 70: 8045-8054
    CrossrefPubMedGoogle Scholar
  • 37 Dean E, Middleton MR, Pwint T et al. Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. Br J Cancer 2012; 106: 468-474
    CrossrefPubMedGoogle Scholar
  • 38 Liu JF, Tolaney SM, Birrer M et al. A phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer 2013; 49: 2972-2978
    CrossrefPubMedGoogle Scholar
  • 39 Liu JF, Barry WT, Birrer M et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol 2014; 15: 1207-1214
    CrossrefPubMedGoogle Scholar
  • 40 Liu JF, Barry WT, Birrer M et al. A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer. ASCO Annual Meeting. Abstr. LBA5500; presented May 31, 2014.
    PubMedGoogle Scholar